News | September 10, 2007

CellCyte, Cleveland Clinic Qualify Stem Cell Delivery in Damaged Hearts

September 11, 2007 - CellCyte Genetics Corp. has entered into a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte's proprietary compounds, with the goal of increasing volumes of stem cells delivered.

CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart. The goal of this therapy is to increase the number of stem cells delivered to a damaged organ, thereby increasing organ healing and functional restoration. The Company's first product in development, CCG-TH30, is designed to send autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack. In preclinical models, CCG-TH30 has been shown to increase the retention of stem cells up to as much as 80 percent compared to conventional methods, which achieve only up to about 7 percent. Importantly, CellCyte’s product can be delivered intravenously through the patients’ circulatory system without an invasive procedure.

The lead investigators of the project at Cleveland Clinic Foundation are Dr. Wilson Tang M.D. and Dr. Sathyamangla Prasad Ph.D., both accomplished and renowned scientists in the field of cardiac biology. Dr. Tang is also a physician and key opinion leader in cardiac medicine.

The Cleveland Clinic Foundation scientists will analyze heart tissue samples of heart failure patients for the presence of surface receptors that are hypothesized to play an important role in the interaction of stem cells with the heart. These studies are expected to provide valuable novel information that will increase the understanding of cardiac regeneration and will thereby support the discovery and development of novel stem cell therapeutics for the heart. Work on the project is expected to start in October 2007.

For more information: www.clevelandclinic.org and www.cellcyte.com

Related Content

Placental Stem Cells Can Regenerate the Heart After Heart Attack
News | Stem Cell Therapies | May 20, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta...
ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019
Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of...
FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Overlay Init